Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.

Abstract

According to data presented at the 2017 American Society of Oncology (ASCO) Annual Meeting, with more than 4 years of follow-up, ibrutinib continues to provide clinical utility in chronic lymphocytic leukemia (CLL). However, treatment of CLL patients with high-risk cytogenetics features remains a challenge and the outcome of these hard-to-treat patients is dismal. At the 2017 ASCO Meeting, results of the GENUINE phase III trial showed that, by adding ublituximab, a glycoengineered, anti-CD20 type 1 monoclonal antibody, to ibrutinib, the overall response rate (ORR), complete response rate (CRR), and minimal residual disease (MRD) negativity may be improved in high-risk CLL patients. A further way to improve the results obtained with Bruton's tyrosine kinase (BTK) inhibitors is the parallel use of ibrutinib with chimeric antigen receptor (CAR) T-cell therapy. Through this investigational approach, the rate of MRD negativity was shown to be higher, implying potential eradication of CLL. These novel data indicate that ibrutinib continues to have a positive effect in CLL.

• Authors: Stefano Molica
• Journal: BMC medicine (BMC Med) Vol. 15 Issue 1 Pg. 156 (08 16 2017) ISSN: 1741-7015 [Electronic] England
• PMID: 28810856 (Publication Type: Clinical Conference, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Piperidines
• Pyrazoles
• Pyrimidines
• ibrutinib
• Adenine
• ublituximab

Topics

• Adenine (analogs & derivatives)
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Piperidines
• Pyrazoles (administration & dosage, therapeutic use)
• Pyrimidines (administration & dosage, therapeutic use)